Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Denali Therapeutics Initiates Phase 2a Clinical Study of LRRK2 Inhibitor BIIB122 for Parkinson’s Disease Quiver Quantitative, Inc. - Thu Dec 5, 5:20PM CST

Denali Therapeutics initiates a Phase 2a study of BIIB122 for LRRK2-associated Parkinson's disease, evaluating safety and biomarkers.Quiver AI SummaryDenali Therapeutics Inc. has announced the start of...

DNLI : 21.45 (-0.19%)
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease GlobeNewswire - Thu Dec 5, 7:00AM CST

DNLI : 21.45 (-0.19%)
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights GlobeNewswire - Wed Nov 6, 3:01PM CST

DNLI : 21.45 (-0.19%)
Healthcare (names A - H) - Bio-Techne Corp logo and data-by Piotr Swat via Shutterstock
Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector? Barchart - Wed Sep 25, 9:33AM CDT

Bio-Techne has underperformed the healthcare sector over the past year, yet analysts remain strongly bullish about the stock’s prospects.

TECH : 73.17 (+2.49%)
XLV : 138.00 (+1.26%)
DNLI : 21.45 (-0.19%)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List PR Newswire - Wed Sep 27, 2023

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer PR Newswire - Mon Sep 11, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner PR Newswire - Tue Aug 29, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)

Barchart Exclusives

Is It Time to Sell This Second-Fiddle AI Stock Before 2025? Barchart - 3 minutes ago
Bank of America has cut its rating on AMD while lowering its price target. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot